BPH/LUTS: Heart Healthy = Prostate Healthy

  • Mark A. Moyad


Aging, genetics, and a family history of BPH/LUTS can profoundly increase the risk of these conditions. Yet the observation that prescription alpha-blocker (originally designed to reduce blood pressure) medications could quickly reduce BPH severity for some men, along with decades of lifestyle research, now suggests that BPH prevention and perhaps partial treatment may occur via heart-healthy processes. Almost all documented heart-healthy interventions or lifestyle changes can prevent some aspect of BPH/LUTS. Moderate alcohol intake, blood pressure, glucose, lipid, caloric, and weight control, and exercise and increased vegetable, fiber, and plant omega-3 intakes are just some of the many lifestyle factors that are gaining consistent data to suggest that this condition can be prevented, delayed, and partially treated with heart-healthy behaviors. However, heart-unhealthy lifestyle changes could also lead to profound increases in the risk and need for treatment for BPH/LUTS. The time is now for clinicians to embrace, practice, and promote heart-healthy behaviors to men concerned about BPH/LUTS. Heart health equals prostate health. This mantra is easy to say but difficult to comply with, which is why there is a need to constantly emphasize the overwhelming amount of old and new data that suggest that BPH/LUTS is a lifestyle-impacted condition for many men around the world.


Caloric Restriction Prostate Volume International Prostate Symptom Score International Prostate Symptom Score Score Prostate Cancer Prevention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Moyad MA. Lifestyle changes to prevent BPH: heart-healthy=prostate healthy. Urol Nurs. 2003;23:439–41.PubMedGoogle Scholar
  2. 2.
    Moyad MA, Lowe FC. Educating patients about lifestyle modifications for prostate health. Am J Med. 2008;121(8 Suppl 2):S34–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Kupelian V, McVary KT, Barry MJ, Link CL, Rosen RC, Aiyer LP, et al. Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health Survey. Urology. 2009;73:950–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Partin AW, Page WF, Lee BR, Sanda MG, Miller RN, Walsh PC. Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology. 1994;44:646–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Sanda MG, Beaty TH, Stutzman RE, Childs B, Walsh PC. Genetic susceptibility of benign prostatic hyperplasia. J Urol. 1994;152:115–9.PubMedGoogle Scholar
  6. 6.
    Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, et al. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol. 1997;157:876–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Rohrmann S, Fallin MD, Page WF, Reed T, Partin AW, Walsh PC, et al. Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins. Epidemiology. 2006;17:419–27.PubMedCrossRefGoogle Scholar
  8. 8.
    Faruque MS, Alam MK, Ullah MA, Rahman MH, Kibria MG, Haque MM, et al. Evaluation of transurethral ethanol ablation of prostate for symptomatic benign prostatic hyperplasia. Mymensingh Med J. 2012;21:265–9.PubMedGoogle Scholar
  9. 9.
    Goya N, Ishikawa N, Ito F, Ryoji O, Tokumoto T, Toma H, Yamaguchi Y. Ethanol injection therapy of the prostate for benign prostatic hyperplasia: preliminary report on application of a new technique. J Urol. 1999;162:383–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Savoca G, De Stefani S, Gattuccio I, Paolinelli D, Stacul F, Belgrano E. Percutaneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: preliminary report. Eur Urol. 2001;40:504–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Platz EA, Rimm EB, Kawachi I, Colditz GA, Stampfer MJ, Willett WC, et al. Alcohol consumption, cigarette smoking, and risk of benign prostatic hyperplasia. Am J Epidemiol. 1999;149:106–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Gass R. Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. BJU Int. 2002;90:649–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Crispo A, Talamini R, Gallus S, Negri E, Gallo A, Bosetti C, et al. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. Urology. 2004;64:717–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;167:925–34.PubMedCrossRefGoogle Scholar
  15. 15.
    Lee YJ, Jeong SJ, Byun SS, Lee JJ, Han JW, Kim KW. Prevalence and correlates of nocturia in community-dwelling older men: results from the Korean Longitudinal Study on Health and Aging. Korean J Urol. 2012;53:263–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Parsons JK, Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol. 2009;182:1463–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Shen W, Yao HQ, Deng ZX, Zhang XM, Zhang LC, Hu WL. Arteriosclerotic risk factors and benign prostatic hyperplasia. Zhonghua Nan Ke Xue. 2010;16:29–33.PubMedGoogle Scholar
  18. 18.
    de Mey C. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being. Eur Urol. 1998;34 Suppl 2:18–28.CrossRefGoogle Scholar
  19. 19.
    Abdollah F, Briganti A, Suardi N, Castiglione F, Gallina A, Capitanio U, et al. Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J Urol. 2011;52:507–16.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhang X, Zhang J, Chen J, Zhang C, Li Q, Xu T, et al. Prevalence and risk factors of nocturia and nocturia-related quality of life in the Chinese population. Urol Int. 2011;86:173–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Bravi F, Bosetti C, Dal Maso L, Talamini R, Montella M, Negri E, et al. Food groups and risk of benign prostatic hyperplasia. Urology. 2006;67:73–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Prezioso D, Catuogno C, Galassi P, D’Andrea G, Castello G, Pirritano D. Life-style in patients with LUTS suggestive of BPH. Eur Urol. 2001;40 Suppl 1:9–12.PubMedCrossRefGoogle Scholar
  23. 23.
    Signorello LB, Tzonou A, Lagiou P, Sarnoli E, Zavitsanos X, Trichopoulos D. The epidemiology of benign prostatic hyperplasia: a study in Greece. BJU Int. 1999;84:286–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Patil H, Lavie CJ, O’Keefe JH. Cuppa joe: friend or foe? Effects of chronic coffee consumption on cardiovascular and brain health. Mo Med. 2011;108:431–8.PubMedGoogle Scholar
  25. 25.
    Heilbronn LK, Ravussin E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am J Clin Nutr. 2003;78:361–9.PubMedGoogle Scholar
  26. 26.
    Varady KA, Roohk DJ, Hellerstein MK. Dose effects of modified alternate-day fasting regimens on in vivo proliferation and plasma insulin-like growth factor-1 in mice. J Appl Physiol. 2007;103:547–51.PubMedCrossRefGoogle Scholar
  27. 27.
    Blando J, Moore T, Hursting S, Jiang G, Saha G, Beltran L, et al. Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev Res (Phila). 2011;4:2002–14.CrossRefGoogle Scholar
  28. 28.
    Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006;106:320–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Khoo J, Piantadosi C, Duncan R, Worthley SG, Jenkins A, Noakes M, et al. Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. J Sex Med. 2011;8:2868–75.PubMedCrossRefGoogle Scholar
  30. 30.
    Coker RH, Williams RH, Yeo SE, Kortebein PM, Bodenner DL, Kern PA, et al. The impact of exercise training compared to caloric restriction on hepatic and peripheral insulin resistance in obesity. J Clin Endocrinol Metab. 2009;94:4258–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int. 2008;101:313–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Freeman MR, Solomon KR. Cholesterol and benign prostate disease. Differentiation. 2011;82:244–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62:27–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Sutcliffe S, Giovannucci E, De Marzo AM, Willett WC, Platz EA. Sexually transmitted infections, prostatitis, ejaculation frequency and the odds of lower urinary tract symptoms. Am J Epidemiol. 2005;162:898–906.PubMedCrossRefGoogle Scholar
  35. 35.
    Sutcliffe S, Rohrmann S, Giovannucci E, Nelson KE, De Marzo AM, Issacs WB, et al. Viral infections and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey. J Urol. 2007;178:2181–5.PubMedCrossRefGoogle Scholar
  36. 36.
    St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal anti-inflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006;164:760–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology. 2008;72:813–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Padayatty SJ, Marcelli M, Shao TC, Cunningham GR. Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab. 1997;82:1434–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Marino G, Pugno E, Cevoli R, Griffa D, Pastorini S, Cocimano V. Phamracologic treatment of benign prostatic hypertrophy (BPH): a combination of mepartricin and simvastatin. Analysis and results. Minerva Urol Nefrol. 1991;43:279–82.PubMedGoogle Scholar
  40. 40.
    Stamatiou KN, Zaglavira P, Skolarikos A, Sofras F. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol. 2008;34:555–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Kim WT, Yun SJ, Choi YD, Kim GY, Moon SK, Choi YH, et al. Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J Korean Med Sci. 2011;26:1214–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Parson JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178:395–401.CrossRefGoogle Scholar
  44. 44.
    Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8:29–36.PubMedCrossRefGoogle Scholar
  45. 45.
    Hammarsten J, Hogstedt B. Calculated fast-growing benign prostatic hyperplasia—a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol. 2002;36:330–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Sarma AV, St Sauver JL, Hollingsworth JM, Jacobson DJ, McGree ME, Dunn RL, et al. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men. Urology. 2012;79:102–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Wang Z, Olumi AF. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation. 2011;82:261–71.PubMedCrossRefGoogle Scholar
  48. 48.
    Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG. Insulin-like growth factor axis abnormalities in prostate stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1994;79:1410–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Boudon C, Rodier G, Lechevallier E, Mottet N, Barenton B, Sultan C. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J Clin Endocrinol Metab. 1996;81:612–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Wang Z, Ikeda K, Wada Y, Foster HE, Weiss RM, Latifpour J. Expression and localization of basic fibroblast growth factor in diabetic rat prostate. BJU Int. 2000;85:945–52.PubMedCrossRefGoogle Scholar
  51. 51.
    Park Y, Subar AF, Hollenbeck A, Schatzkin A. Dietary fiber intake and mortality in the NIH-AARP diet and health study. Arch Intern Med. 2011;171: 1061–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Eshak ES, Iso H, Date C, Kikuchi S, Watanabe Y, Wada Y, et al. Dietary fiber intake is associated with reduced risk of mortality from cardiovascular disease among Japanese men and women. J Nutr. 2010;140:1445–53.PubMedCrossRefGoogle Scholar
  53. 53.
    Moreyra AE, Wilson AC, Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med. 2005;165: 1161–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Agrawal AR, Tandon M, Sharma PL. Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects. Int J Clin Pract. 2007;61:1812–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Streppel MT, Arends LR, van’t Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med. 2005;165:150–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Vernay M, Aidara M, Salanave B, Deschamps V, Malon A, Oleko A, et al. Diet and blood pressure in 18–74 year old adults: the French Nutrition and Health Survey (ENNS, 2006–2007). J Hypertens. 2012;30(10):1920–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Marlett JA, McBurney MI, Slavin JL, for the American Dietetic Association. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc. 2002;102: 993–1000.PubMedCrossRefGoogle Scholar
  58. 58.
    Kaczmarczyk MM, Miller MJ, Freund GG. The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer. Metabolism. 2012;61:1058–66.PubMedCrossRefGoogle Scholar
  59. 59.
    Barnard RJ, Kobayashi N, Aronson WJ. Effect of diet and exercise intervention on the growth of prostate epithelial cells. Prostate Cancer Prostatic Dis. 2008;11:362–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Tariq N, Jenkins DJA, Vidgen E, et al. Effect of soluble fiber diets on serum prostate specific antigen in men. J Urol. 2000;163:114–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Pan A, Yu D, Demark-Wahnefried W, Franco OH, Lin X. Meta-analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr. 2009;90: 288–97.PubMedCrossRefGoogle Scholar
  62. 62.
    Rodriguez-Leyva D, Dupasquier CM, McCullough R, Pierce GN. The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Can J Cardiol. 2010;26:489–96.PubMedCrossRefGoogle Scholar
  63. 63.
    Bravi F, Bosetti C, Dal Maso L, Talmini R, Montella M, Negri E, et al. Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia. Urology. 2006;67:1205–11.PubMedCrossRefGoogle Scholar
  64. 64.
    Denmark-Wahnefried W, Robertson CN, Walther PJ, Polascik TJ, Paulson DF, Vollmer RT. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation on benign prostatic epithelium and prostate-specific antigen. Urology. 2004;63:900–4.CrossRefGoogle Scholar
  65. 65.
    Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin IV MT, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008;17:3577–87.PubMedCrossRefGoogle Scholar
  66. 66.
    Zhang W, Wang X, Liu Y, Tian H, Flickinger B, Empie MW, et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. J Med Food. 2008;11:207–14.PubMedCrossRefGoogle Scholar
  67. 67.
    Zhang W, Wang X, Liu Y, Tian H, Flickinger B, Empie MW, Sun SZ. Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercholesterolaemic subjects. Br J Nutr. 2008;99:1301–19.PubMedGoogle Scholar
  68. 68.
    Fukumitsu S, Aida K, Shimizu H, Toyoda K. Flaxseed lignan lowers blood cholesterol and decreases liver disease risk factors in moderately hypercholesterolemic men. Nutr Res. 2010;30:441–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Moyad MA. No bogus science health advice. Ann Arbor, MI: Spry; 2010.Google Scholar
  70. 70.
    Geller J, Sionit L, Partido C, Li L, Tan X, Youngkin T, et al. Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture. Prostate. 1998;34:75–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Ambrosini GL, de Klerk NH, Mackerras D, Leavy J, Fritschi L. Dietary patterns and surgically treated benign prostatic hyperplasia: a case control study in Western Australia. BJU Int. 2008;101:853–60.PubMedCrossRefGoogle Scholar
  72. 72.
    Wong WC, Wong EL, Li H, You JH, Ho S, Woo J, et al. Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial. J Altern Complement Med. 2012;18:54–60.PubMedCrossRefGoogle Scholar
  73. 73.
    Anderson JW, Bush HM. Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. J Am Coll Nutr. 2011;30:79–91.PubMedCrossRefGoogle Scholar
  74. 74.
    Erdman Jr JW. Soy protein and cardiovascular disease: a statement for healthcare professionals from the nutrition committee of the AHA. Circulation. 2000;102:2555–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M, et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. 2006;113:1034–44.PubMedCrossRefGoogle Scholar
  76. 76.
    Hamilton-Reeves JM, Vazquez G, Duval SJ, Phipps WR, Kurzer MS, Messina MJ. Clinical studies show no effects of soy protein or isoflavones on reproductive hormones in men: results of a meta-analysis. Fertil Steril. 2010;94:997–1007.PubMedCrossRefGoogle Scholar
  77. 77.
    Demark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects of hormonal levels, prostate-specific antigen, and histopathologic features. Urology. 2001;58:47–52.PubMedCrossRefGoogle Scholar
  78. 78.
    Rohrmann S, Giovannucci E, Willett WC, Platz EA. Fruit and vegetable consumption, intake of nutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr. 2007;85:523–9.PubMedGoogle Scholar
  79. 79.
    Galeone C, Pelucchi C, Talamini R, Negri E, Dal Maso L, Montella M, et al. Onion and garlic intake and the odds of benign prostatic hyperplasia. Urology. 2007;70:672–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Araki H, Watanabe H, Mishina T, Nakao M. High-risk group for benign prostatic hypertrophy. Prostate. 1983;4:253–64.PubMedCrossRefGoogle Scholar
  81. 81.
    Gu F. Changes in the prevalence of benign prostatic hyperplasia in China. Chin Med J (Engl). 1997;110:163–6.Google Scholar
  82. 82.
    Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53:1228–35.PubMedCrossRefGoogle Scholar
  83. 83.
    Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140: 989–1002.PubMedGoogle Scholar
  84. 84.
    Platz EA, Kawachi I, Rimm EB, Colditz GA, Stampfer MJ, Willett WC, et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med. 1998;158:2349–56.PubMedCrossRefGoogle Scholar
  85. 85.
    Gann PH, Hennekens CH, Longcope C, Verhoek-Ottedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 1995;26:40–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54:935–44.PubMedCrossRefGoogle Scholar
  87. 87.
    Jung S, Lee EN, Lee SR, Kim MS, Lee MS. Tai chi for lower urinary tract symptoms and quality of life in elderly patients with benign prostate hypertrophy: a randomized controlled trial. Evid Based Complement Alternat Med. 2012;2012: 624692.PubMedGoogle Scholar
  88. 88.
    Yeh GY, Wang C, Wayne PM, Phillips RS. The effect of tai chi exercise on blood pressure: a systematic review. Prev Cardiol. 2008;11:82–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Nguyen MH, Kruse A. A randomized controlled trial of Tai chi for balance, sleep quality and cognitive performance in elderly Vietnamese. Clin Interv Aging. 2012;7:185–90.PubMedCrossRefGoogle Scholar
  90. 90.
    Sea J, Poon KS, McVary KT. Review of exercise and the risk of benign prostatic hyperplasia. Phys Sportsmed. 2009;37:75–83.PubMedCrossRefGoogle Scholar
  91. 91.
    Kang D, Andriole GL, Van De Vooren RC, Crawford D, Chia D, Urban DA, et al. Risk behaviours and benign prostatic hyperplasia. BJU Int. 2004;93: 1241–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Sarma AV, Jacobson DJ, St Sauver JL, Lieber MM, Girman CJ, Nehra A, et al. Smoking and acute urinary retention: the Olmsted County study of urinary symptoms and health status among men. Prostate. 2009;69:699–705.PubMedCrossRefGoogle Scholar
  93. 93.
    Yun AJ, Doux JD. Opening the floodgates: benign prostatic hyperplasia may represent another disease in the compendium of ailments caused by global sympathetic bias that emerges with aging. Med Hypotheses. 2006;67:392–4.PubMedCrossRefGoogle Scholar
  94. 94.
    Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs. 2002;62 Suppl 2:1–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Park HY, Sin D. Smoking kills, quitting heals: the importance of smoking cessation in COPD. Clin Respir J. 2011;5:185–6.PubMedCrossRefGoogle Scholar
  96. 96.
    Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2009;182(6 Suppl):S27–31.PubMedCrossRefGoogle Scholar
  97. 97.
    Lee RK, Chung D, Chughtai B, Te AE, Kaplan SA. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int. 2012;110:540–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Khoo J, Piantadosi C, Worthley S, Wittert GA. Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes (Lond). 2010;34:1396–403.CrossRefGoogle Scholar
  99. 99.
    Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, et al. BJU Int. 2006;98: 1038–42.PubMedCrossRefGoogle Scholar
  100. 100.
    Fowke JH, Munro H, Signorello LB, Blot WJ, Penson DF, Urologic Diseases of America Project. Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med. 2011;26:1305–10.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Mark A. Moyad
    • 1
  1. 1.Department of UrologyUniversity of Michigan Medical CenterAnn ArborUSA

Personalised recommendations